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Structural mosaic abnormalities are large post-zygotic mutations present in a subset of cells and have been implicated in
developmental disorders and cancer. Such mutations have been conventionally assessed in clinical diagnostics using cyto-
genetic or microarray testing. Modern disease studies rely heavily on exome sequencing, yet an adequate method for
the detection of structural mosaicism using targeted sequencing data is lacking. Here, we present a method, called
MrMosaic, to detect structural mosaic abnormalities using deviations in allele fraction and read coverage from next-gener-
ation sequencing data. Whole-exome sequencing (WES) and whole-genome sequencing (WGS) simulations were used to cal-
culate detection performance across a range of mosaic event sizes, types, clonalities, and sequencing depths. The tool was
applied to 4911 patients with undiagnosed developmental disorders, and 11 events among nine patients were detected. For
eight of these 11 events, mosaicism was observed in saliva but not blood, suggesting that assaying blood alone would miss
a large fraction, possibly >50%, of mosaic diagnostic chromosomal rearrangements.
[Supplemental material is available for this article.]
Genetic mutations that arise post-zygotically lead to genetic het-
erogeneity in an organism, a phenomenon called mosaicism.
The detection of mosaic mutations that are small (single-base or
indel) is still a great technical challenge, but can be achieved in
specific experimental setups to restrict the number of candidate
mutations (e.g., matched tumor-normal samples in cancer to dis-
cover somatic mutations) (Genovese et al. 2014; Jaiswal et al.
2014). However, multi-megabase (structural) mosaic rearrange-
ments are now routinely detected using cytogenetics and microar-
ray technology (Miller et al. 2010; Biesecker and Spinner 2013).
Recent single-nucleotide polymorphism (SNP) microarray-based
studies have demonstrated that mosaic structural abnormalities
are implicated in developmental disorders (Conlin et al. 2010;
King et al. 2015), increase in incidence with age (Forsberg et al.
2012), and predispose to hematological malignancies in adults
(Jacobs et al. 2012; Laurie et al. 2012).
Modern SNP microarray technology is well suited for detect-
ing mosaicism, because probe density is high (often above 1 mil-
lion sites per genome) and probes generate allele ratio data with
high signal-to-noise ratio. SNP microarray platforms assess two
metrics useful for mosaicism detection: (1) b allele frequency
(BAF), the fraction of the alleles at a locus representing the less-
common allele; and (2) log R ratio (LRR), a measure of copy num-
ber, based on the log ratio of signal intensity compared to a refer-
ence. These metrics are affected differently depending on the
nature of the structural abnormality: whereas copy-neutral (loss
of heterozygosity [LOH]) mosaicism results in a deviation of BAF
alone, copy-number (gain or loss) mosaicism additionally alters
the LRR. Absolute deviation from genotype-expected BAF (e.g.,
0.5 for AB genotype), called B-deviation (Bdev), occurs inmosaic re-
gions when the locus has a mixture of genotypes from wild-type
andmosaic tissue. Several software tools, such as Partek Genomics
Suite, Illumina cnvPartition, BAFsegmentation (Staaf et al. 2008)
and Mosaic Alteration Detection (MAD) (González et al. 2011),
harness this deviation as a mosaic signal. MAD is open source
and has been recently used in several large SNP-based mosaicism
projects (Forsberg et al. 2012, 2014; Jacobs et al. 2012); it identifies
mosaic segments using aberrations in Bdev and then labels aberrant
segments as copy-loss, copy-gain, or copy-neutral events based on
the alteration of the LRR frombaseline, a deviation referred to here
as copy-deviation, or Cdev. In contrast to loss of heterozygosity,
other types of balanced structural variants, notably inversions
and balanced translocations, do not typically disrupt BAF or LRR,
cannot typically be detected using these methods, and are not ad-
dressed in this study.
Developmental disorders (DD) are often caused by rare, small
(SNV and indel) mutations, genetic variation that is not easily cap-
tured using microarray (King et al. 2014). Therefore, to achieve a
more comprehensive assessment of pathogenic mutations, rare
disease studies rely heavily on targeted sequencing of the
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protein-coding regions (“exons”) of the genome, an approach
called whole-exome sequencing (WES) (Koboldt et al. 2013).
Indeed, sequencing of the whole genome (WGS) offers several ad-
vantages compared to WES, including greater breadth of the ge-
nome and more consistent coverage of exons (Meynert et al.
2014). However, WGS is not currently as widely used as WES for
rare disease studies due to higher costs, so thiswork focuses primar-
ily on exome-sequencing data.
In addition to small-scale variation, forms of large-scale
“structural variation,” including copy-number (Lee et al. 2007)
and copy-neutral variation (uniparental disomy [UPD]) (Yama-
zawa et al. 2010), are also important causes of DD. CNV burden
analysis of nearly 16,000 children with DD (Cooper et al. 2011)
demonstrated that nearly all CNVs >2 Mb are likely pathogenic
(odds ratios for CNVs of 1.5 and 3 Mb were 20 and 50, respective-
ly), and deletion events are more often penetrant than duplication
events. UPD events are only present in approximately one in 3500
healthy individuals (Robinson 2000), but are enriched in children
with DD (King et al. 2014) and may result in highly penetrant im-
printing disorders, recessive diseases, or may be associated with
chromosomal mosaicism (Eggermann et al. 2015). Low-clonality
mosaicism is difficult to observe in karyotyping, as inspection of
at least 20 cells is required to exclude 14% mosaicism with 95%
confidence (Hook 1977), and it is also difficult to observe inmicro-
array analysis, because the detection sensitivity of mosaic duplica-
tions by SNP microarray with about 1 million probes for events of
at least 2 Mb in size is limited to events of ∼10% clonality (Gonzá-
lez et al. 2011; Jacobs et al. 2012; Laurie et al. 2012; Machiela et al.
2015). Themedian average clonality in recent SNP-based studies of
DD for mosaic aneuploidy was 40% (Conlin et al. 2010), and for
mosaic structural variation (2 Mb and greater), it was 44% (King
et al. 2015). With regard to frequency of mosaicism among chil-
dren investigated with clinical diagnostic testing, the proportion
of autosomal mosaic copy-neutral events was 0.24% (12 in 5000)
(Bruno et al. 2011), whereas the proportion of autosomal mosaic
copy-number events was 0.35% (36 in 10,362) (Pham et al.
2014); summing both copy-neutral and copy-number proportions
yields a combined proportion of 0.59% of cases withmosaic struc-
tural variation.
Thedetectionof large-scale genetic variation fromWESdata is
challenging because input data are derived using sparse sampling
of the genome, because targeted regions typically cover only ∼2%
of the genome (Meynert et al. 2014) and sequence read depth at ex-
ons is biased by enrichment efficiency and other factors (Plagnol
et al. 2012). Despite these limitations, exome-based software tools
have been successfully engineered to detect large-scale constitutive
mutations, including copy-number variation (Sathirapongsasuti et
al. 2011; Fromer et al. 2012; Krumm et al. 2012; Magi et al. 2013;
Backenroth et al. 2014) and copy-neutral variation, such as
BCFtools/RoH (Narasimhan et al. 2016) and UPDio (King et al.
2014). These tools are relatively insensitive tomosaic abnormalities
(post-zygotic abnormalities, i.e., “mutations”), however, because
they typically rely on single metrics, such as copy-number change
(rather than copy-number and allele-fraction), or on genotype,
which is not well assessed in mosaic state. Specialized methods
have been developed for the analysis of cancer exomes where tu-
mor and normal tissue can be isolated (Lonigro et al. 2011;
Amarasinghe et al. 2014) or, in the context of a parent-fetus trio,
for fetal DNA inmaternal plasma (Rampášek et al. 2014). However,
a method to detect copy-number and copy-neutral mosaicism
from an individual’s exome (or genome) is lacking, but if available,
could further extend the capacity of sequence-based analyses.
We developed MrMosaic, a method that detects structural
mosaicism using joint analysis of Bdev and Cdev in targeted or
whole-genome sequencing data (Fig. 1). We used simulations to
demonstrate the superior performance of MrMosaic compared to
the MAD algorithm. We also applied MrMosaic to analyze WES
data from 4911 children with developmental disorders and identi-
fied 11 structural mosaic events in nine individuals, six of whom
exhibited tissue-specific mosaicism.
Results
We developed a new computational method, MrMosaic, to detect
structural mosaic abnormalities (copy number and loss of hetero-
zyosity) from high-throughput sequence data (Methods). In sum-
mary, this method identifies chromosomal segments with
elevated deviations in allelic proportion and copy number, relative
Figure 1. Detecting structural mosaicism using MrMosaic. (A) Exome
data are stored in a BAM file from which allele fraction (left) and coverage
(right) are measured at polymorphic positions within or near target re-
gions. A simulatedmosaic deletion is depicted. (B) The raw data, consisting
of BAFs (y-axis: B allele frequency) and normalized coverage (y-axis: log ra-
tio of normalized coverage) are plotted across chromosome space (x-axis)
for a simulatedmosaic deletion. (C ) Absolute deviation of BAF (y-axis: Bdev)
and normalized coverage (y-axis: Cdev) at heterozygous sites are analyzed.
A smoothed median has been included. (D) Mann-Whitney U tests were
performed separately for Bdev and Cdev, comparing the signal detected in
sliding windows in this chromosome compared with randomly selected
sites from other chromosomes, generating a test statistic (y-axis). A
smoothed median has been included. (E) The test statistics are depicted
in log scale. The P-values of the Mann-Whitney U tests were combined
and segmented (black lines). Segments passing the Mscore significance
threshold are plotted in blue.
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to randomly selected sites on other chromosomes from the same
data (Fig. 1). Initially, measures of deviation of allelic proportion
(Bdev) and copy number (Cdev) are calculated from the WES/WGS
data at well-covered (at least seven reads) known polymorphic
SNVs. Whereas Bdev is only assessed at heterozygous sites, Cdev ex-
tracts and integrates read-depth information from flankingnonhe-
terozygous sites to reduce noise. The statistical significance of the
observed Bdev and Cdev were assessed separately, using nonpara-
metric testing, and the resultant P-values were subsequently com-
bined and then segmented using the GADA algorithm (Pique-Regi
et al. 2008). We devised a confidence score, the Mscore, to curate
putative detections of mosaic segments, by integrating metrics
that discriminate between true positive and false positive mosaic
detections (Methods).
Simulations
We performed simulations (Methods) to explore the performance
of MrMosaic for three different classes of structural mosaicism:
gains, losses, and LOH, in several contexts. The variation in perfor-
mance across mosaicism of different sizes, clonalities, and se-
quencing coverage is summarized in Figure 2, for both WES and
WGS data.
Across all measured categories, mosaic duplications were
more difficult to identify than deletion or LOH events, especially
at lower (25%) clonality (Supplemental Fig. S1). We suspected
that the most likely explanation for this lower sensitivity is that
duplications result in the smallest deviation of Bdev compared
with deletion and LOH events (Supplemental Fig. S2), and the
Cdev signal ismasked by sampling noise at low clonality. To further
explore the effect of including Cdev in addition to Bdev, we investi-
gated the performance of MrMosaic using Bdev alone compared
with joint analysis of Bdev and Cdev. This analysis showed substan-
tially improved detection of copy-number events above lower
clonality, whereas only a marginally decreased performance of
LOH detection (Supplemental Fig. S3), consistent with the intui-
tion that Cdev yields a valuable net signal when clonality is above
the Cdev noise floor.
Simulation performance increased with larger event size (Fig.
2A). WES simulation analysis demonstrated high area under the
precision-recall curve (AUC) for all events at least 10 Mb in size
and at least 50% in clonality, and for deletion and loss of heterozy-
gosity (LOH) events, at least 5 Mb in size. MrMosaic performed fa-
vorably compared to MAD in all measured categories. Results for
WGS simulations demonstrated an AUC of about 0.9 for 100 kb
LOH and loss events and >0.95 for all megabase-size events.
Larger events were assayed by more positions, and whole-genome
simulations interrogated nearly 50-fold more sites than exome
data (Supplemental Table S1).
Detection performance in simulations increased between
25% and 75% clonality (Fig. 2B). TheWES andWGS clonality per-
formance results were measured at 5 Mb and 100 kb sizes, respec-
tively, as events at these sizes were most sensitive to changes in
clonality (Supplemental Figs. S4, S5). Previous studies of children
with DD have reported a median mosaicism of ∼40% mosaicism,
and detection performance is strong for detecting mosaicism at
this clonality at the studied sizes. As clonality increases, the mosa-
icism is present in a greater proportion of cells, resulting in a great-
er signal of detection.
Simulation performance increases with respect to sequencing
coverage (Fig. 2C). TheWES andWGS performancewith respect to
sequencing coverage were assessed for events of 50% clonality,
Figure 2. Simulation performance summarized by AUC. We measured
the average precision (area under the precision-recall curve [AUC]) for
MrMosaic implemented on whole-exome (WE) simulations (A,C,E) and
MrMosaic and MAD implemented on whole-genome (WG) simulations
(B,D,F). The depth, size, and coverage measured for WES and WGS simu-
lations were selected to accentuate informative differences in perfor-
mance. AUC across size: Simulated events of 50% clonality were studied
for WES (A) and WGS (B) simulations. Although for WES simulations, sim-
ulated exome depth was 75× depth, for WGS simulations, it was 30×
depth. MrMosaic on whole-genome data (WG-MrM) outperforms
MrMosaic on exome data (WE-MrM), which outperforms MAD on exome
data (WE-MAD). AUC across clonality: Although for WES (C) simulations,
the simulated size and coverage was 5 Mb and 75×, for WGS (D) simula-
tions, it was 100 kb and 30×. AUC across average coverage: Simulated
events of 50% were studied for both WES (E) and WGS (F) simulations.
Although for WES simulations, simulated event size was 5 Mb, for WGS
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using 5-Mb events for the WES simula-
tions and100-kb events for theWGS sim-
ulations. WES simulations demonstrated
a marginal improvement of detection
performance at higher coverage, which
was notable for midclonality gains
(Supplemental Fig. S4). Previous work
suggested that 75× average coverage in
WES data is sufficient for constitutive
copy-number analysis (Fitzgerald et al.
2014), and these coverage simulations
demonstrated that this exome coverage
is also sufficient for the detection of mo-
saic structural abnormalities. In the
WGS results, AUC rose dramatically be-
tween 15× and 20× for LOH and loss
events and between 25× and 30× for
gains. AUC was above about 0.9 for LOH
and loss events at 30× depth, a standard
sequencing depth used in WGS disease
studies. Nearly all structural mosaic
events of 100 kb and 50% clonality were
detected (Supplemental Fig. S5), and av-
erage coverage of 20× was sufficient to
detect nearly all 50% clonality deletion
and LOH events at 100 kb, and detection
performance of gains improved at 30×
and 40× (Supplemental Fig. S6). This
improved performance as coverage in-
creases results primarily from sampling
variance (“noise”) decreasing (correla-
tion r =−0.95) (Supplemental Fig. S7),
with an additional minor contribution
from more sites (more signals) passing
the minimal depth threshold for consid-
eration (Supplemental Table S1).
Detections in 4911 exome samples
WegeneratedWESdata for 4911 children
with undiagnosed developmental disor-
ders. DNA was collected from either
blood (n = 1652), saliva (n = 3246), or
both (n = 13), and sequenced to amedian
average coverage of 90×. Analysis for
structural mosaicism identified 11 mosa-
ic abnormalities amongnine individuals,
a frequency of 0.18%. The detections
consisted of five losses (median size: 13
Mb; median clonality: 46%), four gains
(median size: 25 Mb; median clonality:
55%), and two LOHs (median size: 50
Mb; median clonality: 26%) (Fig. 3; Table 1; Supplemental Figs.
S8–S18).
To improve our understanding of the accuracy of this se-
quencing-based method, we compared the results of the above
analysis with the results of a prior experiment (King et al. 2015),
whichhad analyzedhigh-resolution SNPdata of 1303Deciphering
Developmental Disorders (DDD) samples, among which 1226 (of
the 1303) had both exome and SNP data available. Among these
1226 for which the exome data could be compared with the
gold-standard SNP data, detection usingMrMosaic identified eight
events, whereas detection using SNP microarray data of probands
identified 10 events. Of the two events not detected by exome but
detected by SNP microarray, one of the missed events was a 4-Mb
duplication below 25% clonality. The other missed event was an
LOH event with low sequencing depth (33×, one of the lowest of
our study) (Supplemental Fig. S19); low depth results in higher
sampling variance and lower statistical significance of deviations
in allelic proportion and copy number (Supplemental Fig. S7).
Given the high clonality (∼75%) of this event, it may have been
detected using constitutive (genotype-based) UPD analysis;
Figure 3. Structural mosaicism detected from exome data: Structural Mosaicism Detected by
MrMosaic in the Deciphering Developmental Disorders (DDD) study. Black and red dots represent
copy number and allele fraction, respectively. Cdev and Bdev are plotted in black and red trend lines.
The blue line represents statistically significant segmented detections passing a threshold. Different
classes of events are found: (A–C) Mosaic gains; (D–F) mosaic losses; (G) mixed copy number; (H,I )
loss-of-heterozygosity events.
Detection of structural mosaicism
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however, because paternal data were not available for this sample,
it was not analyzed by our trio-based UPD detection pipeline (King
et al. 2014).
Validation of the 11mosaic abnormalities using SNPmicroar-
rays on DNA derived from both blood and saliva successfully de-
tected all abnormalities in at least one tissue (Table 1). Notably,
six of the seven mosaic copy-number mutations detected by
MrMosaic in exome data had been undetected by both clinical
and high-resolution aCGH investigation of the same tissue, de-
spite most events being at least 5 Mb in size and exhibiting 50%
clonality (Supplemental Table S2). Examination of the raw
aCGH data in one case (Supplemental Fig. S17) showed that only
small fragments of one of the eventswere detected, but these called
segments were individually much smaller than the actual event.
Detection of the mosaic events was largely dependent on the
assayed tissue, suggesting the importance of tissue-specificity
(present in only a subset of tissues) in mosaicism detection. Of
the 11 mosaic events, three were detected in blood and in saliva
samples, whereas the remaining eight were only observed in saliva
(Table 1; Supplemental Figs. S8–S18). There were two abnormali-
ties detected from 1652 blood samples and nine detected from
3246 saliva samples, a nonsignificant proportional difference (P
> 0.05, Fisher’s exact test). One of the mosaic events detected in
both blood and saliva was an LOH-type event, remarkable for hav-
ing a gradient of increasing clonality toward the telomere (Sup-
plemental Figs. S16, S19). This gradient of increasing clonality
along the chromosome is compatible with LOH-mediated mosaic
reversion, characterized by distinct cell populations carrying par-
tially overlapping independent LOH events, as reported recently
(Choate et al. 2015). Nevertheless, despite generation and analysis
of high-depth (∼400×)WES data for this sample and the identifica-
tion of several strong candidate genes, including CEP57 (the cause
of mosaic aneuploidy syndrome) (Snape et al. 2011) in the rever-
sion-localized region, no plausibly pathogenic rare (<1% minor
allele frequency) coding sequence variants were identified (Sup-
plemental Table S4). It may be that the gene of interest is several
megabases distal to the breakpoint region.
We assessed the pathogenicity of the events detected in these
nine children based on their phenotypes and known genomic dis-
orders whose phenotypes matched those found in these children.
Of the nine children presented here, four (Decipher IDs: 261373,
259003, 260462, and 257978) had been discovered and examined
for pathogenicity during an earlier study (see Table 2; Supplemen-
tal Note S1; King et al. 2015). Themosaic events identified in seven
of nine children were considered definitely pathogenic because
they weremulti-megabase CNVs that overlap known genomic-dis-
order regions (Supplemental Note S1). The reversion mosaic event
was considered indicative of a likely pathogenicmutation, because
the presence of multiple overlapping mosaic clones suggests
strong and on-going negative selection against a deleterious allele.
One LOH event was of uncertain pathogenicity as no rare loss of
function or functional variants were detected (Supplemental
Table S4).
Empirical evaluation of detection of mosaicism from WGS data
One sample, with three mosaic abnormalities detected on a single
chromosome, which had also been detected during an earlier anal-
ysis (King et al. 2015), provided a valuable opportunity to use
whole-genome sequencing data to clarify rearrangement archi-
tecture and to demonstrate MrMosaic performance on whole-
genome sequence data. After the whole-genome sequencing
data were generated and analyzed, MrMosaic easily detected these
multi-megabase mosaic events, found with Mscores of 36, 117,
and 32. The presence of three mosaic events of similar clonality
on the same chromosome is suggestive of a complex chromosomal
rearrangement. Analysis of the WGS read-pair data using
BreakDancer (Chen et al. 2009) identified read pairs mapping
across the centromere and evidence of a breakpoint spanning
from the q-arm deletion to the centromere. Ring chromosomes
are associated with biterminal deletions (Guilherme et al. 2011)
and inverted duplications (Knijnenburg et al. 2007). Additionally,
all three mosaic components arose from a single parental origin
(paternal, in this case) (King et al. 2015), which would be expected
Table 1. Detections by exome and validation by SNP microarray
Exome detections SNP validation











265800 12 Gain 988,894 33,535,510 0.201 0.140 Saliva 1.34 0.68a Absent
261373 12 Gain 283,642 33,535,289 0.131 0.262 Saliva 0.72 0.45a Absent
273553 18 Gain 670,541 18,534,702 0.186 0.185 Saliva 1.18 0.6a Absent
259003 22 Loss 42,912,136 50,717,129 0.131 −0.129 Blood 0.42 0.54 0.34
274013 10 Loss 121,717,932 134,916,366 0.159 −0.324 Saliva 0.48 0.44 Absent
274600 18 Loss 48,458,662 76,870,586 0.190 −0.434 Saliva 0.55 0.49 Absent
260462 18 Loss 662,103 2,740,714 0.171 −0.339 Saliva 0.51 0.46 Absent
260462b 18 Gain 12,702,610 15,323,214 0.118 0.263 Saliva 0.41 0.5 Absent
260462 18 Loss 48,466,843 74,962,645 0.153 −0.345 Saliva 0.47 0.45 Absent
257978 5 LOH 146,077,526 179,731,635 0.167 −0.002 Blood 0.33 0.24 0.26
274396 11 LOH 66,834,252 134,126,612 0.255 −0.0047 Saliva 0.51 0.28 0.17
The 11 mosaic abnormalities detected in the nine samples with exome data were validated using SNP microarray chips. All exome detections were vali-
dated in at least one tissue. In the majority of cases (8 of 11), the variant was detected in only one of two assayed tissues, and in all such cases, the
variant was detected in saliva but not in blood. Clonality was calculated from Bdev using Equation 2 (Supplemental Table S7) and ranged from 17% to
68%. This calculation is based on the assumption that the mosaic event is an alteration of a single allele. However, this calculated clonality is an overes-
timate for one of the events, which was found (by previous FISH analysis) (King et al. 2015) to be a mosaic tetrasomy, and two others were are suspect-
ed to also be rearrangements of multiple alleles (another gain of Chromosome 12p and one gain of Chromosome 18p, thought to reflect mosaic
tetrasomy 18).
aAdjusted tetrasomy clonality.
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in a ring chromosome. We suspected that the underlying abnor-
mality in this child is a ring chromosome, although we were un-
able to access the cellular material required to generate the
cytogenetic data to prove this hypothesis (Supplemental Fig. S21).
Discussion
Structural mosaic abnormalities are multi-megabase, post-zygotic
mutations that have previously been associated with developmen-
tal disorders (Conlin et al. 2010; King et al. 2015). This work
introduces a novel method to detect these mutations from next-
generation sequencing data.
In an extensive simulation study, we show adequate discrim-
inative ability to detect abnormalities inWES andWGS data across
a large, clinically relevant range of size and clonality in different
types of mosaic structural variation. We also compare our method
to the popular array-based mosaic detection method, MAD, and
show a substantial boost in performance, which derives primarily
from the joint analysis of allelic proportion and copy-number de-
viations. Simulation results suggested that exome sequencing data
can be used to identify many of the known clinical mosaic dupli-
cations involving chromosome-arm events, such as 12p and 18p
mosaic tetrasomy, because MrMosaic easily detected events of
this size. Given the dimensionality of the simulation parameter
space (i.e., clonality, event size, coverage) and the computational
cost of running these simulations, we restricted our analysis to pa-
rameter values in line with previous observations of structural
mosaicism and reasonable experimental parameters at current se-
quencing costs. Additionally, we also chose more extreme param-
eter values for size and clonality in order to illustrate the dynamic
range of the method in high-depth whole-genome sequence data
(e.g., performance at <100-kb resolution and low clonality events),
although few previous pathogenic variants with these characteris-
tics have previously been described. These simulated performances
only serve as illustrations for the selected parameter set and are not
readily generalizable to other combinations of parameters, given
the nonlinear interaction between parameters. Overall, simulation
results show that MrMosaic is able to detect variants similar to pre-
viously described pathogenic variants with good performance.
We used MrMosaic to uncover pathogenic structural mosai-
cism in a large exome study of childrenwith undiagnosed develop-
mental disorders. Applying our method to the exome data of 4911
enrolled children, we identified nine individuals with structural
mosaicism; the majority of these mutations were considered
pathogenic. Assessment of pathogenicity was largely based on
identifying substantial overlap between the known syndromic
manifestations of large, well-known syndromic disorders, and
the predominant phenotypes seen in each child. In one child
with LOH-mosaicism, no pathogenic mutations were identified
in the mosaic LOH region, suggesting that a pathogenic allele
may lie outside of this mosaic region. In this WES-based analysis,
we recovered eight of the 10 abnormalities previously detected
in a subset of 1226 samples previously analyzedwith SNP genotyp-
ing chip data, suggesting that exome-analysis alone is sensitive to
detecting large-scale mosaicism. One of the missed abnormalities
was likely undetected because the exome data were of low depth,
which increases the variance of measured Bdev and Cdev. Most of
the detected mosaic copy-number abnormalities had escaped
detection by previous aCGH analysis. This demonstrates that
detection of mosaic events requires assay of tissue containing the
abnormality and tailored methods with sufficient sensitivity for
mosaicism.
The overall frequency of mosaicism detected in this study,
0.18%, is lower and significantly different (P < 10−4, binomial
test) from the 0.59% structural mosaicism frequency estimated
from previous studies. One likely explanation for the discrepancy
in these frequencies is ascertainment bias, as some classes of struc-
tural mosaicism (e.g., mosaic trisomies) are likely to have been di-
agnosed by prior diagnostic testing (e.g., karyotype or microarray)
and not enrolled into the DDD study. Another component of this
discordance may be due to decreased sensitivity, as mosaicism
smaller than 2 Mb is challenging to detect by exome, and these
small events account for ∼25% (9/36) of mosaic copy number
events described previously (Pham et al. 2014). Given the low
number of mosaic events in our cohort, due to the lowmosaicism
rate and tissue specificity, and the lack of publicly available large-
scale developmental disorder data sets, this study only provides a
limited estimate of the real-life performance of MrMosaic on non-
simulated data sets. As developmental disorder studies increase in
sample size and scope, we envision that screening for mosaicism
will provide additional explanatory power, increasing the number
of diagnosed cases.
In one sample, we observed a gradient of mosaicism, a phe-
nomenon likely associated withmosaic reversion of a de novomu-
tation dominantly inducing genome instability. Analysis of the
mosaic LOH region with high-depth exome data did not identify
Table 2. Phenotypes for children with identified structural mosaicism
Decipher ID Phenotypes
257978 Intellectual disability profound, seizures, somnolence, thoracolumbar scoliosis, gastroesophageal reflux, abnormality of neuronal
migration
259003 Generalized hypotonia, global developmental delay
260462 Microcephaly, muscular hypotonia, short philtrum, upslanted palpebral fissure
261373 Moderate global developmental delay
265800 Global developmental delay, meningocele, delayed closure of the anterior fontanelle, macroglossia, sparse scalp hair, ligamentous
laxity, delayed speech and language development, coarse facial features
273553 Global developmental delay, joint laxity, hypermetropia, strabismus
274013 Severe expressive language delay, global developmental delay, abnormal facial shape, brachydactyly syndrome, thick hair, coarse facial
features, abnormality of facial musculature, joint stiffness
274396 Congenital hypothyroidism, congenital microcephaly, moderately short stature, mild global developmental delay, premature anterior
fontanel closure, fine hair, sparse scalp hair, long palpebral fissure, wide mouth, short broad hands, excessive wrinkling of palmar
skin, excessive skin wrinkling on dorsum of hands and fingers, strabismus, generalized hypopigmentation of hair, progressive
hyperpigmentation, mixed hypo- and hyperpigmentation of the skin, axillary and groin hyperpigmentation and hypopigmentation
274600 Microcephaly, progressive microcephaly, severe global developmental delay, abnormal posturing, brachycephaly, epicanthus, muscular
hypotonia, narrow palate, hypotelorism, broad distal phalanx of finger
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a strong candidate coding variant, and a furtherWGS-based search
for candidate pathogenic de novo mutations is on-going. Whole-
genome sequencing data were generated for one individual with
three mosaic abnormalities on the same chromosome. Analysis
of these data recapitulated the mosaic events, and read pair analy-
sis identified a pericentromeric inversion and supported the hy-
pothesis of an underlying complex chromosomal rearrangement,
likely a ring chromosome.
As expected, whole-genome analysis had superior perfor-
mance compared to exome analysis, which was likely due to a
combination of advantages of whole-genome data, including
higher density of assayed sites (by nearly 50-fold) andmore consis-
tent coverage across sites, compared to exome coverage, which is
subject to exome bait hybridization biases. Compared towhole-ge-
nome data, the exome data had higher average coverage (75× to
25×) for sites within targeted regions compared to the whole-ge-
nome data, and although simulation results showed increasing
performance with higher depth sequence data, this effect was out-
weighed by the greater density of sites in whole-genome data.
Although the general performance of the method is adequate
inmany clinically relevant cases, some classes of event provemore
difficult to detect. For example, low clonality mosaic gains gener-
ate the smallest deviation in Bdev andCdev compared to other types
of events, explaining their comparatively poor detection sensitiv-
ity in simulations and the failure to detect one mosaic duplication
found using SNP data but not in exome data. More lenient detec-
tion thresholdsmay be preferred to increase detection sensitivity if
clinical suspicion ofmosaic duplication exists. Increasing the clon-
ality of mosaicism by the biopsy of affected tissue, as is performed
when pigmentarymosaicismprovides evidence of underlyingmo-
saicism (Woods et al. 1994), should also theoretically improve
detection. Given the size and clonality of the two missed events
and the simulation results from whole-genome sequencing, both
events would likely have been detected had they been analyzed us-
ing higher depth WES or WGS, which are likely to become more
common in the future.
The majority of the mosaic events we observed in saliva-de-
rived DNAwere not observed in blood. The samples with these ab-
normalities were recruited into our study because they remained
undiagnosed after assessment by clinical laboratories of blood-de-
rived DNA failed to detect themosaic abnormalities we detected in
saliva. DNA derived from saliva has a mixed origin, mainly lym-
phocytes (derived from mesoderm) and epithelium (derived
from epiderm) (Endler et al. 1999); therefore, the events detected
in saliva, but not blood, are believed to reflect epithelial mosai-
cism. There are two possible explanations for the disparity in tissue
distribution we observed, first, that the epithelium-derived muta-
tional events occurred late, i.e., after the differentiation of lympho-
cytes and epithelial cells; or second, that these events occurred
early, i.e., prior to the split between lymphocytes and epithelial
cells with subsequent removal from blood cell lineages by purify-
ing selection. Several lines of evidence suggest the second ex-
planation is more likely: (1) existing precedent, as the second
phenomenon has been directly observed in Pallister-Killian syn-
drome, in which the percentage of abnormal cells decreases with
age in blood but not fibroblasts (Conlin et al. 2012), and tissue-lim-
ited mosaicism has been observed in mosaic tetrasomies of
Chromosomes 5p, 8p, 9p, and 18p (Choo et al. 2002); (2) the clon-
ality of events observed in both blood and saliva is not greater than
the clonality of events in only saliva, which would be expected if
events seen across tissue arose earlier in development; and (3)
both observed LOH events are shared between tissues but only
one of nine CNV events are shared between tissues, perhaps sug-
gesting increased pathogenicity of CNV events compared to
copy-neutral events, thus, more likely to be negatively selected
in blood. Given these considerations underlying the disparity in
tissue type and the observation that the majority of observed ab-
normalities were detected in saliva but not blood, it is possible
that, compared to the sampling of saliva, the sampling of blood
could lead to a substantial loss of power (possibly <50% power)
to detect pathogenic structural mosaicism, resulting in missed di-
agnoses. Studying the saliva tissue in these children permitted
the identification of their mosaic abnormalities and ended for
them and their families, their quest for diagnosis.
Additional work is required to investigate for which develop-
mental disorders tissue-limitedmosaicism is common. Another in-
triguing question regarding tissue distribution is the relationship
between clonality and pathogenicity. Althoughmosaicism limited
to a small number of cells is unlikely to cause developmental disor-
ders, it is conceivable that low-level mosaicism present in a vulner-
able tissue, such as white matter neurons, may have clinical
consequences. More work is needed to address this question, in-
cluding more extensive analysis of the tissue distribution of mosa-
icism (for example, by analyzing diverse tissues sampled from all
three germ layers) and assays with improved resolution, allowing
single or oligo-cell sequencing. The availability of more sensitive
detection methods will improve the detection of a larger fraction
of events limited to a single tissue.
Next-generation sequencing, in the form of exome and
genome sequencing, can be harnessed to detect a wide range of
mutations, including, as presented here, mosaic structural abnor-
malities. Given that sequencing costs continue to decline and
because of the multifaceted detection capabilities of exome data,
it may be that exome sequencing will supersede microarray tech-
nology as a first-line test for developmental disorders. Widespread
incorporation of high-depth exome and whole-genome sequenc-
ing will revolutionize our understanding of the extent of mosai-




Implementing mosaic detection requires generating an input file
and executing the algorithm; the latter consists of several steps:
statistical testing, segmentation, filtering, and results visualiza-
tion. “BAF” is used below as an alias for “nonreference propor-
tion.” The input data for MrMosaic consist of genomic loci with
measured Bdev values, Cdev values, and genotypes, stored in a tab-
delimited file. The loci selected were diallelic single-nucleotide
polymorphic (1%–99% MAFs among European individuals in
the UK10K project) (UK10K Consortium 2015) autosomal posi-
tions. For exome analysis, only loci overlapping targeted regions
of the exome design were used. At these loci, Bdev and Cdev values
were calculated as described in the following two paragraphs.
Bdev values were generated using the following method: the
identity of the alleles at each locus is extracted using fast_pileup
function in the Perl module Bio::DB::Sam (Stajich et al. 2002), us-
ing high-quality reads (removal criteria: below base quality Q10,
below mapping quality Q10, improper pairs, soft- or hard-clipped
reads), and BAF was calculated as the number of reference bases di-
vided by the total of reference bases and nonreference bases.
Heterozygous sites were defined as loci with a BAF between 0.06
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as the absolute difference between the BAF and 0.5. Only loci with
sufficient read coverage (at least seven reads)were used for analysis.
Cdev values were generated using the following method: read
depths from each target region were collected, the log2 ratio for
that target region was calculated by comparing its read depth to
a reference read depth, in which the reference value was defined
as the median read depth among the distribution of read depths
at that target region from dozens of highly correlated samples.
This log2 ratio was normalized based on several covariates pertain-
ing to each target region (covariates included were GC-content,
hybridization melting temperature, delta free energy) (Fitzgerald
et al. 2014). Lastly, using the Aberration Detection Algorithm v2
(ADM2) method by Agilent, a final error-weighted value is pro-
duced, which we used as the Cdev value.
The statistical testing step of the MrMosaic algorithm begins
by data smoothing, using a rolling median (width of 5) across het-
erozygote and homozygous sites, to utilize the depth information
in homozygous sites to reduce variance. From this point forward,
only heterozygote sites were considered, as mosaic abnormalities
do not affect Bdev of homozygous loci. Statistical testing assesses
whether a given locus is significantly deviated from the Bdev and
Cdev means given the null hypothesis of no chromosomal abnor-
mality. At every heterozygote site, we compute two Mann-
Whitney U tests, one for Bdev and one for Cdev, testing the alterna-
tive hypothesis that the distribution of themetric in the neighbor-
hood of the chosen site is greater (has a higher median rank) than
the distribution of the background. We use 10,000 randomly se-
lected sites from all autosomes, excluding the current chromo-
some, as the background population. In order to account for
nonuniform spacing of the data points, we applied a distance-
weighted resampling scheme, to down-weight distant points
from the chosen site. The tricube distance, inspired by Loess
smoothing, was chosen as a decay function for the resampling
weights and considered data points up to 0.5 Mb upstream of
and downstream from the given position. An equal number of
data points were then sampled around the chosen site and from
the background (n = 100) and the Mann-Whitney U test was per-
formed. Finally, we combined the P-values of the two statistical
tests (one for Bdev and Cdev) for every position using Fisher’s
Omnibus test.
The segmentation stepoperates on the combinedP-value gen-
erated above. Segmentation was performed using the GADA algo-
rithm (González et al. 2011), using the parameters values as
follows: SBL step: maxit of 1 × 107; Backward Elimination step: T-
value of 10 andMinSegLen value of 15. This step generates contig-
uous segments of putative chromosomal abnormalities. Segments
in close proximity (within 1 Mb) that show the same signal direc-
tion (loss, gain, LOH) are merged to reduce oversegmentation.
The filtering step is required to assess which of the segments
generated above are likely reflective of true mosaicism.While test-
ing MrMosaic in exome simulation analyses, we observed that
true-positive detections (those overlapping simulated events)
tended to be larger (greater number of probes) and have stronger
evidence of deviation (GADA amplification value) than putative
segments that did not overlap simulated regions (i.e., false-
positive, spurious calls) (Supplemental Figs. S22–S24). We cap-
tured these two features in a scoringmetric calculated from the cu-
mulative empirical distribution functions for “number of probes”
and “GADAamplification value” of false-positive segments and as-
sessed the composite probability that a given segment comes from
these distributions, such that: Mscore = abs[−log2(x) +−log2(y)],
where x and y refer to these empirical cumulative distribution func-
tions. Thus, theMscore is a quality-control metric derived by com-
bining the size and signal-strength of detections. We used the
Mscore to filter those events least likely to represent false positives.
We selected events with an Mscore of 8 or greater for analysis,
because we observed that this appeared to provide a good balance
between sensitivity and specificity (Supplemental Fig. S24).
The visualization step generates a detection table and detec-
tion plots. The detection table consists of mosaic abnormalities
detected and contains the following data: chromosome,
start_position, end_position, log2ratio_of_segment, bdev_of_seg-
ment, clonality, type, number_of_probes, GADA_amplification,
p_val_nprobes, p_val_GADA_amplification, Mscore. Event clonal-
ity was calculated by assessing the type of mosaic event based on
LRR and converting the Bdev value to clonality based on the type
of event (Supplemental Table S6). The detection plots are png files
showing the loci and BAF and Cdev data for each chromosome in
which a mosaic abnormality is detected, as well as a genome-
wide lattice plot using the data for all chromosomes.
The algorithm can be used in multithreaded mode to facili-
tate whole-genome analysis. Analysis of a single whole exome us-
ing a single thread was completed in 15 min when tested using a
single core of an Intel Xeon 2.67 Ghz processor and 500 MB of
RAM. Whole-genome analysis using 24 cores required 30 GB of
RAM and 7 h. Whole-genome analysis can be substantially short-
ened if the number of sliding windows is reduced or the window
size is increased.
Simulating mosaicism
We devised a series of simulation experiments to assess MrMosaic
performance for various events, across type (LOH, gains, losses),
clonalities, sequencing depths, platforms (whole-exome [WE]
and whole-genome [WG]) and to compare performance to the
MAD method. We compared performance to a modified version
ofMAD thatwe adapted to enablemore flexible execution in a par-
allel-computing environment, but identical with respect to statis-
tical methods.
The simulation method consisted of the following steps: (1)
loci selection, (2) calculating depth at these loci, (3) parameter
space and number of trials, (4) adjusting read depth in simulated
regions, (5) calculating final read depth, (6) selecting sites based
on minimum depth, (7) calculating relative copy-number, (8) as-
signing genotypes, (9) calculating the BAF for each site, and (10)
calculating performance. Steps 1–3 differed between the WES
and WGS simulations and are described below. The remaining
steps 4–10 were executed consistently for WES and WGS simula-
tions and are described next.
For WES simulations, loci selection (1) was based on diallelic
single-nucleotide polymorphic positions—between 1% and 99%
UK10K (UK10KConsortium 2015) Europeanminor allele frequen-
cy—in the V3 version of the target-region design. To calculate
depth at these loci (2), at each locus i, baseline sequence read depth
(˜DPi) for these sites was defined as the median of the read depth
distribution among 100 parental exomes for each site, considering
only high-quality reads (mapQ≥ 10, baseQ≥ 10, properlymapped
read pairs), where parental exomes had amean average sequencing
output of 67× (calculated as the number of QC-passed andmapped
reads without read-duplicates × 75 bp read length/96 Mb targeted
bp). The parameter space (3) consisted of the following: target
average sequencing coverage (in ×) ∈ {50, 75, 100}, event clonality
m∈ {0.25, 0.375, 0.5, 0.75}, type∈ {loss, gain, LOH}, and size∈ {2 ×
106, 5 × 106, 1 × 107, 2 × 107}. Two hundred trials (4) were
conducted per parameter combination for a total of 36,000
simulations.
For WGS simulations, the loci selection (1) was based on
diallelic single-nucleotide polymorphic (1%–99% European
MAFs from the May 2013 release of The 1000 Genomes Project)
(The 1000 Genomes Project Consortium 2012) autosomal
Detection of structural mosaicism
Genome Research 1711
www.genome.org
 Cold Spring Harbor Laboratory Press on November 10, 2017 - Published by genome.cshlp.orgDownloaded from 
positions. To calculate depth at these loci (2), we calculated a scal-
ing factor for each locus based on themedian read depthof the first
two median absolute deviations of the distribution of coverage for
that site seen across 2500 low-coverage samples in The 1000
Genomes Project (The 1000 Genomes Project Consortium 2012).
A site-specific scaling factor was calculated as the deviation of
each site’s read depth from the average read depth across all poly-
morphic positions. Simulation depth was defined at each site as
the desired simulation coverage multiplied by site-specific scaling
factor. The parameter space (3) consisted of two experiments: (1)
average genome coverage of 25×, event clonality m ∈ {0.25,
0.375, 0.5, 0.75}, type {loss, gain, LOH}, and size (Mb) ∈ {1 × 105,
2 × 106, 5 × 106}; and (2) a 5-Mb 50% clonality event captured at
average genome coverages (in ×)∈ {30, 40, 50, 60} for the threemo-
saic types {loss, gain, LOH}. One hundred trials (4) were conducted
per WGS simulation.
The remaining simulations steps 4–10 described below were
performed consistently for WES and WGS simulations. For each
simulation, a single mosaic event was introduced into each simu-
lation trial. The adjustment of read depth in simulated regions (4)
was performed using a scaling factor based on the type and clonal-
ity of the simulated event, m, while sites not overlapping copy-
number simulated events would not undergo this scaling step
(Supplemental Table S6). To calculate the final simulated read
depth (5) for each site i (SDPi), we sampled from a Poisson distribu-
tion with λi equal to the scaled read depth. Only positions with a
final read depth (6) of at least 7 were included for analysis.
Relative copy-number (7) was defined as log2 of the ratio of the fi-
nal read depth to the baseline read depth.
The assignment of genotypes (8) (AA, AB, or BB) at each posi-
tion, i, was randomly determined based on the site’s minor allele
frequency, which was used in a multinomial function with proba-
bilities corresponding to Hardy Weinberg–assumed genotype
proportions (p2, 2pq, q2). For calculating the BAF for each hetero-
zygote at site i (9), we adjusted the expected heterozygote propor-
tion of 0.5 with respect to the chosen event type and clonality and
sampled from a binomial distribution given this adjusted propor-
tion and the simulated read depth at i. BAFs for homozygote refer-
ence (AA) and nonreference (BB) sites were chosen by sampling
from a binomial distributionwith P = 0.01 or P = 0.99, respectively,
and the simulated read depth at i.
MrMosaic and MAD were applied on the simulated WES and
WGS samples generated by the preceding procedure, and perfor-
mance was measured using precision-recall metrics (10). A “suc-
cess” in a trial was considered a detection overlapping the
simulated mosaic event. Precision was calculated as the number
of successes divided by the number of detections. Recall was de-
fined as the proportion of trials with a success.
Description of samples and sequencing
The samples used in this analysis derived from the Deciphering
Developmental Disorders study, a proband two-parent trio-based
investigation of children with undiagnosed developmental disor-
ders from the United Kingdom and Ireland (Firth and Wright
2011; Fitzgerald et al. 2014; Wright et al. 2014; King et al. 2015).
DNA was extracted from blood and saliva and was processed at
the Wellcome Trust Sanger Institute by array CGH and exome se-
quencing. There were 4926 DNA samples analyzed in this study
from 4911 children, because some children were analyzed using
both blood and saliva. The majority, 3260 of 4926 (66%), of the
DNA samples were extracted from saliva.
DNA was enriched using an Agilent exome kit, based on the
Agilent Sanger Exome V3 or V5 backbone and augmented with 5
Mb of additional custom content (Agilent Human All Exon V3
+/V5+, ELID # C0338371). An “extended target region”workspace
was defined by padding the 5′ and 3′ termini of each target region
by 100 bp, yielding a total analyzed genome size of ∼90 Mb.
Sequencing was performed using the Illumina HiSeq 2500 plat-
form with a target of at least 50× mean coverage using paired-
end sequence reads of 75-bp read length. Measured exome cover-
age ranged from 14× to 155× with a mean of 69× (Supplemental
Fig. S24). Alignment to the reference genome GRCh37-hs37d
was performed by BWA version 0.5.9 (Li and Durbin 2009) and
saved in BAM-format files (Li et al. 2009).
Additionally, two exome samples were processed post hoc
from saliva after SNP genotyping chip analysis showed mosaicism
was present in saliva but absent in blood. These two exome sam-
ples and the exome sample with suspected revertant mosaicism
were processed separately from the exome experiment described
in the previous paragraph. For these three exomes, the Agilent
Sanger Exome V5 target kit was used, and sequence depth ranged
from 387× to 455× coverage (reads = {465,522,627, 483,098,826,
549,766,632} × 75 bp read length/(90 × 106) target-region size).
The sample with suspected underlying mosaic reversion had
549,224,891 QC-passed and mapped reads and 57,165,328 dupli-
cates, therefore, a mapped read coverage of 410× [(549,224,891–
57,165,328)] × 75/(90 × 106).
Sequencingwas performed using an Illumina X-Ten sequenc-
ing machine on the sample for which whole-genome sequencing
data were generated. Library fragments of 450-bp insert size were
used, and paired-end 151-bp read-length sequence reads were gen-
erated. Alignment to the reference genome GRCh37-hs37d was
performed by BWA version 0.5.9 (Li and Durbin 2009) and saved
in BAM-format files (Li et al. 2009). Realignment to GRCh38 was
not done because this method avoids mitochondrial regions and
harnesses exonic regions, whosemapping is unlikely to be affected
by alternate scaffolds. Average coverage was calculated using
SAMtools flagstat as the number of QC-passedmapped-reads with-
out duplicates using 151-bp read-lengths in a 3-Gb genome:
(616,151,282–124,325,581) × 151/(3 × 109) = 24.8×. Rearrangement
analysis was carried out using BreakDancer v1.0 (Chen et al. 2009).
Additional filtering implemented in addition to Mscore
quality score
Some events with very high Mscores appeared to represent real,
but constitutive, abnormalities. There were two failure modes we
identified: constitutive duplications and homozygosity by descent
(HBD). Constitutive duplications genuinely produce strong signals
in MrMosaic, but also constitutive deletion and ROH events may
produce putative detections if individual probes had mapping ar-
tifacts that resulted in spurious signals. We used BCFtools/RoH
to identify and filter HBD regions, and we flagged as suspicious
events with >25% reciprocal overlap with CNVs detected through
constitutive copy-number detection. In addition, we observed sev-
eral recurrent putative detections, especially prevalent in pericen-
tromeric and acrocentric regions that appeared spurious on the
basis of inconsistencies between BAF and LRR, and we filtered
such systematic errors by filtering putative mosaic events seen in
>2.5% of samples. The remaining putative detections were each
manually reviewed. Tissue specificity was assessed through manu-
al review of each detection in both saliva and blood (Supplemental
Note S1).
SNP genotyping chip validation
Illumina HumanOmniExpress-24 Beadchips (713,014 markers)
were used to ensure that both saliva and blood tissuewere analyzed
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the validation experiment, SNP microarray chips were run on
blood samples for IDs 261373, 273553, 259003, 260462, and
257978. Illumina GenomeStudio software was used to generate
log R ratio and BAF metrics, and Illumina Gencall software was
used to calculate genotypes. Structural mosaic detection was per-
formed using MAD (González et al. 2011). Initial mosaic events
were merged if events were within 1 Mb and were the same type
(loss, gain, or LOH) ofmosaic event. Results were plotted using cus-
tom R code.
Software availability
MrMosaic is primarily written in the R language, available as
an open source tool at GitHub (https://github.com/asifrim/
mrmosaic).MrMosaic source code is available in the Supplemental
Material.
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